Current Controversies in the Management of Myeloma Bone Disease

Rebecca Silbermann, G. David Roodman

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti-myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone-targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti-myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti-resorptive therapy, risks and benefits of long term anti-resorptive therapy, and whether anti-resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. J. Cell. Physiol. 231: 2374–2379, 2016.

Original languageEnglish (US)
Pages (from-to)2374-2379
Number of pages6
JournalJournal of Cellular Physiology
Volume231
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Bone Diseases
Bone
Anabolic Agents
Diphosphonates
Proteasome Endopeptidase Complex
Therapeutics
Bone and Bones
Paraproteinemias
Bone Resorption
Disease Management
Multiple Myeloma
Appointments and Schedules
Morbidity
Survival
Mortality

ASJC Scopus subject areas

  • Physiology
  • Medicine(all)
  • Clinical Biochemistry
  • Cell Biology

Cite this

Current Controversies in the Management of Myeloma Bone Disease. / Silbermann, Rebecca; Roodman, G. David.

In: Journal of Cellular Physiology, Vol. 231, No. 11, 01.11.2016, p. 2374-2379.

Research output: Contribution to journalReview article

@article{6cc4b4b4816449fd8d6078987eb974c5,
title = "Current Controversies in the Management of Myeloma Bone Disease",
abstract = "Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti-myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone-targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti-myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti-resorptive therapy, risks and benefits of long term anti-resorptive therapy, and whether anti-resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. J. Cell. Physiol. 231: 2374–2379, 2016.",
author = "Rebecca Silbermann and Roodman, {G. David}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/jcp.25351",
language = "English (US)",
volume = "231",
pages = "2374--2379",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Current Controversies in the Management of Myeloma Bone Disease

AU - Silbermann, Rebecca

AU - Roodman, G. David

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti-myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone-targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti-myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti-resorptive therapy, risks and benefits of long term anti-resorptive therapy, and whether anti-resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. J. Cell. Physiol. 231: 2374–2379, 2016.

AB - Recent significant advances in the treatment of multiple myeloma have resulted in an improvement in median overall survival from 4.6 years, for patients diagnosed between 2001 and 2005, to 6.1 years, for those diagnosed between 2006 and 2010 (Kumar et al., 2014). However, myeloma bone lesions persist in the absence of active disease and continue to be frequent and significant causes of patient morbidity and contribute to mortality. While bisphosphonate therapy in combination with anti-myeloma therapy remains the cornerstone of skeletal disease management in myeloma, open questions regarding the optimal management of patients with myeloma bone disease remain. This article will address when to initiate and stop bone-targeted therapy in patients with monoclonal gammopathies, duration of bisphosphonate treatment in the era of more effective anti-myeloma treatment, the role of bone resorption markers in determining the dosing schedule for anti-resorptive therapy, risks and benefits of long term anti-resorptive therapy, and whether anti-resorptive therapies should be stopped to enhance the potential anabolic effects of proteasome antagonists and other anabolic agents. J. Cell. Physiol. 231: 2374–2379, 2016.

UR - http://www.scopus.com/inward/record.url?scp=84978427656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978427656&partnerID=8YFLogxK

U2 - 10.1002/jcp.25351

DO - 10.1002/jcp.25351

M3 - Review article

C2 - 26910829

AN - SCOPUS:84978427656

VL - 231

SP - 2374

EP - 2379

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 11

ER -